The Impact of Surgeon Referral and a Radiation Oncologist Productivity-Based Metric on Radiotherapy Receipt Among Elderly Women with Early-Stage Breast Cancer: Analysis from a Tertiary Cancer Network

Mira A Patel (✉ patelm@mskcc.org)

Memorial Sloan Kettering Cancer Center <https://orcid.org/0000-0002-4926-5128>

Elaine E. Cha

Memorial Sloan Kettering Cancer Center

Stephanie Lobaugh

Memorial Sloan Kettering Cancer Center Department of Epidemiology & Biostatistics

Zhigang Zhang

Memorial Sloan Kettering Cancer Center Department of Epidemiology & Biostatistics

Beryl McCormick

Memorial Sloan Kettering Cancer Center

Lior Z. Braunstein

Memorial Sloan Kettering Cancer Center

Oren Cahlon

Memorial Sloan Kettering Cancer Center

Simon N. Powell

Memorial Sloan Kettering Cancer Center

Monica Morrow

Memorial Sloan Kettering Cancer Center Department of Surgery

Atif Khan

Memorial Sloan Kettering Cancer Center

Erin F. Gillespie

Memorial Sloan Kettering Cancer Center

Research Article

Keywords: Radiotherapy, breast neoplasms, referral and consultation, clinical decision-making

Posted Date: July 30th, 2021

DOI: <https://doi.org/10.21203/rs.3.rs-708312/v1>

License: © ⓘ This work is licensed under a Creative Commons Attribution 4.0 International License. [Read Full License](#)

Abstract

Purpose: Guidelines for early-stage breast cancer allow for radiotherapy (RT) omission following breast conserving surgery (BCS) among older women, though high utilization of RT persists. This study explores surgeon referral and the effect of a productivity-based bonus metric for radiation oncologists in an academic institution with centralized quality assurance (QA) review.

Methods: We evaluated patients ≥ 70 years of age treated with BCS for ER+ pT1N0 breast cancer at a single tertiary cancer network between 2015-2018. The primary outcomes were radiation oncology referral and RT receipt. Covariables included patient and physician characteristics, and treatment decisions before versus after productivity metric implementation. Univariable generalized linear effects models explored associations between these outcomes and covariables.

Results: Of 703 patients included, 483 (69%) were referred to radiation oncology and 273 (39%) received RT (among those referred, 57% received RT). No difference in RT receipt pre- versus post- productivity metric implementation was observed ($p=0.57$). RT receipt was associated with younger patient age (70-74 years, OR 2.66, 95% CI 1.54-4.57) and higher grade (grade 3, OR 7.75, 95% CI 3.33-18.07). Initial referral was associated with younger age (70-74, OR 5.64, 95% CI 3.37-9.45) and higher performance status (KPS ≥ 90 , OR 5.34, 95% CI 2.63-10.83).

Conclusion: Non-referral to radiation oncology accounted for half of RT omission, but was based on age and KPS, in accordance with guidelines. Lack of radiation oncologist practice change in response to misaligned financial incentives is reassuring, potentially reflecting centralized QA review. Multi-institutional studies are needed to confirm these findings.

Introduction

While adjuvant radiation is a standard component of breast-conservation [1], multiple randomized controlled clinical trials show that radiation does not improve overall survival, distant metastasis, or rates of subsequent mastectomy among elderly patients with early-stage invasive ER-positive breast cancer [2-4]. As a result, in 2004 the National Comprehensive Cancer Network (NCCN) Guidelines incorporated omission of adjuvant RT as a category I option for older women meeting eligibility criteria for CALGB 9343 [5]. But despite availability of randomized evidence and practice guidelines, management of early-stage invasive breast cancer has remained largely unchanged in the United States. Adjuvant RT use was reduced by only 4% (79% to 75%) between 2001 and 2007 [6], though more recent population-based estimates suggest approximately 60% of patients in this low-risk population receive radiation [7].

Evidence suggests high variability between centers, with the proportion of patients receiving RT ranging from 49% to 93% among NCCN member institutions in 2009 [8]. Since variability can reflect underlying inefficiency and bias, it is important to understand factors potentially driving both physician and patient decision-making. For example, up to 40% of surgeons and 20% of radiation oncologists in a nationally-representative sample incorrectly cite a survival benefit for RT in this cohort [9]; this is important because patients report that trust in their physician's recommendation is one of the most important factors guiding their decision [10]. While data on overall receipt of radiation is known, evidence regarding the role of surgeon referral versus radiation oncologist recommendation are less understood due to limitations of population-based datasets.

Once patients see a radiation oncologist, financial misalignment in a fee-for-service healthcare system could contribute to overtreatment [11]. Evidence supports financial incentives leading to practice change in oncology, most commonly de-prescribing in response to decreased reimbursement for systemic therapy [12]. Additionally, more frequent unnecessary procedures, specifically cystoscopy for bladder cancer, occur in response to increased reimbursement [13]. Little is known about the potential influence of institutional productivity-based bonus metrics, including on the use of unnecessary procedures in radiation oncology, despite this being the predominant practice payment model [14].

The current study was conducted in a large multi-site tertiary care network with a lower than average proportion of patients undergoing radiation (54% as of 2012 [15]) to better understand surgeon referral patterns and radiation treatment decision-making. Specifically, we hypothesized that the enactment of a productivity-based bonus metric for radiation oncologists could have the negative consequence of increasing the proportion of patients receiving RT (among those referred). We also investigate physician, patient, and tumor-related determinants of RT receipt, as well as factors that are associated with initial referral to radiation oncology.

Methods

Dataset and Primary Analysis

This retrospective analysis includes all patients ≥ 70 years of age who underwent breast conserving surgery for ER+ pT1N0 breast cancer between 2015 and 2018 at XXX, a tertiary cancer network with XX clinical practice locations for radiation therapy. Electronic medical records were reviewed for RT receipt (including RT at outside institutions), the primary endpoint. To confirm accuracy in assignment of RT receipt, a second abstractor performed a 10% random sample chart audit [16]. Patients undergoing BCS at outside institutions were not included. Throughout the study period, the Department of Radiation Oncology conducted weekly centralized quality assurance processes (i.e. peer review or “chart rounds”), in which radiation treatment plans for all patients undergoing breast radiation were reviewed by at least two radiation oncologists specializing in breast cancer. Institutional Board Review approval was obtained for this study.

Covariates

Explanatory variables were collected and incorporated into adjusted models. A productivity-based bonus metric was instated for radiation oncologists in January 2017 based on the number of treatment “new starts.” Rather than a Relative Value Units (RVU)-based system that results in incentives for more complex techniques and longer fractionation schedules, at our institution every unique patient treatment course (i.e. ‘new start’) is counted equally. With the implementation of this new metric, physicians have an annual target that reflects an expected minimum number of ‘new start’ treatments per year. Exceeding the annual target can result in a surplus bonus, but is capped at 20% above the target. Previously, a salary-based model without clinical productivity measures was used. Referred patients were thus grouped into ‘pre-metric’ and ‘post-metric’ cohorts to evaluate its effect on practice patterns.

Electronic medical records were reviewed for biologic variables (tumor size, tumor grade, presence of lymphovascular invasion, HER2 status, laterality, focality, Oncotype DX score), patient clinical characteristics (Karnofsky Performance Status score, smoking status, age), patient-reported sociodemographic characteristics (race/ethnicity, highest level of education, preferred language; pulled from intake surveys), types of adjuvant

therapies (chemotherapy, endocrine therapy, radiotherapy), treating physicians (surgeons, radiation oncologists), and radiation clinical practice site. Physician years of experience was estimated from publicly available medical school graduation year. Level of specialization was based on the number of patients treated per physician within this dataset and dichotomized (<10 versus 10 or more consults).

Socioeconomic status (SES) was calculated using the University of Wisconsin's Neighborhood Atlas, as previously reported [17,18]. We determined the national percentile for each patient according to their home address and associated ADI ranking, with 1 indicating the least disadvantaged and 100 indicating the most disadvantaged neighborhood. Distances from patients' homes to the nearest clinic site were calculated using Google Maps [19,20] by selecting the shortest recommended route. Distances were analyzed on a continuous scale and in 5-mile increments, based on prior research [21].

Statistical Analyses

Descriptive statistics were calculated for all variables. Univariable (UVA) generalized linear mixed effects models were used to explore associations between the binary outcome, RT receipt, and explanatory variables of interest among patients referred to radiation oncology. This same approach was used to evaluate associations between initial referral and explanatory variables among all patients. A logit link function was specified for each UVA model, and each included a random intercept and a random slope to account for random variation due to physician. For each surgeon, we reported radiation referral frequency and the median odds ratio (MOR) computed from an intercept-only model with no other fixed effects or random slopes (i.e. only a fixed intercept and random intercept) to quantify the variation between surgeons. Variation in treatment rates among radiation oncologists was demonstrated via a simplified approach, by calculating the median and interquartile range (IQR) of RT rate among those who treated 10 or more patients during the study period. False discovery rate (FDR) adjustments were used to account for multiple comparisons. Results were adjusted within outcomes (RT receipt or radiation oncology referral); for example, RT receipt results were adjusted based on the number of associations with RT receipt that were tested. P-values were deemed significant if they were less than the FDR-adjusted significance threshold. All statistical computations were performed and all output was generated using SAS Software Version 9.4 (The SAS Institute, Cary, NC).

Results

Patient Characteristics

Among 703 patients who met inclusion criteria, 39% (n=273) received RT. The overall median age was 74, and most were non-Hispanic white with a median national SES percentile of 10. Median tumor size was 1.0 cm and most patients presented with grade 2 (56%), HER2 negative disease (96%) without lymphovascular invasion (84%). For the 301 patients (43%) who received an Oncotype DX score, the median score was 15. Nine percent (n=60) of patients received chemotherapy, and endocrine therapy was recommended for 95% (n=666). Patient characteristics pre- and post-metric implementation were comparable, as outlined in **Table 1**.

Covariates Associated with Radiation Receipt

Among 483 patients referred to radiation oncology, 57% (n=273) received RT. The median unadjusted proportion of patients receiving RT from radiation oncologists treating at least 10 patients in the study period (n=14 of 28

total radiation oncologists) was 67% (IQR 54-73), as seen in **Figure 1**. No significant difference was observed in the proportion of patients receiving RT pre- versus post-metric implementation (OR 1.16, 95% CI 0.68-1.98, $p=0.57$). Differences in unadjusted proportion of patients treated over time are shown in **Figure 2**. The only variables significantly associated with RT receipt after adjusting for multiple comparisons were younger patient age (70-74 years, OR 2.66, 95% CI 1.54-4.57, $p=0.001$) and higher tumor grade (grade 3, OR 7.75, 95% CI 3.33-18.07; grade 2, OR 1.83, 95% CI 1.11-3.02; $p<0.001$) (**Table 2**).

Of the 255 patients with RT plans available, 20% ($n=52$) received partial breast irradiation (PBI), which is delivered in 40Gy in 10 fractions, per our institutional standard [22]. The remaining patients received hypofractionated whole breast radiation over 3-4 weeks. The use of PBI did not change with implementation of the productivity metric ($p=0.943$).

Covariates Associated with Referral to Radiation Oncology

The median proportion of patients referred to radiation oncology among surgeons treating at least 10 patients during the study period ($n=16$ out of 17 total breast surgeons) was 77% (IQR 53-82), as seen in **Figure 1**. The MOR that quantifies variation in referral between all surgeons was 2.31. A univariable generalized mixed effects regression model revealed that younger patient age (70-74 years, OR 5.64, 95% CI 3.37-9.45, $p<0.001$) and higher performance status (KPS ≥ 90 , OR 5.34, 95% CI 2.63-10.83, $p<0.001$) were significantly associated with surgeon referral to radiation oncology after adjusting for multiple comparisons (**Table 2**). No other post-FDR significant associations were observed between surgeon referral to radiation oncology and the remaining characteristics.

Discussion

In a large academic center with a relatively low rate of adjuvant radiation among elderly patients with early-stage ER+ breast cancer, we did not observe increased use of radiation in response to a productivity-based financial incentive for radiation oncologists. Approximately half of radiation omission was due to non-referral by surgeons, though this appears appropriate as patient age and KPS was associated with referral. Limited variation between radiation oncologists and lack of additional variables associated with treatment suggests the likely influence of patient preference.

The absence of physician practice change in response to a new financial incentive departs from much, but not all, of the prior literature in oncology [23,24,12,25]. It is therefore important to understand the context in which this finding may apply. In the current study, we tested whether financial misalignment could instigate overtreatment, and found that it did not. In the single institution setting, there is greater potential for the influence of local culture to supersede a financial incentive. We hypothesize that existence of centralized QA of radiation plans in chart rounds helps prevent inappropriate treatment, given the opportunity for peers to inquire about the indication for radiation in low-risk disease, thereby providing feedback to physicians that could influence future decision making. Although the practice of peer review is common in radiation oncology, there is limited data on its efficacy, particularly in the setting of a multi-site network with a centralized process led by subspecialists [26,27]. Understanding the consequences of a capitated productivity-based bonus model in combination with strategies to maintain treatment quality is relevant with the imminent planned implementation of bundled payments through the Radiation Oncology Alternative Payment Model (RO-APM) [28]. This model introduces the potential for physicians to lower their threshold to treat patient populations that previously were *not* routinely receiving treatment, as centers using long-course radiation observe decreased revenues under the new model.

It is notable that approximately half of radiation omission occurred due to non-referral, confirming the critical role of surgeons in the radiation decision-making process. Referral rates were nonetheless considered appropriate given referred patients were younger and healthier (78% with KPS $\geq$ 90), consistent with eligibility criteria for CALGB 9343 and NCCN recommendations [2,3,5]. This is also consistent with institutional guidelines later formalized in 2019 at the multidisciplinary level to make omission the default for patients 75 years or older. From this analysis, we were able to identify older age and lower KPS as factors associated with surgeon non-referral to radiation, which is consistent with institutional guidance for consideration of omission primarily in patients greater than 75 years of age. Additionally, most breast surgeons undertake a discussion with the patient about their tolerance of risk, uncertainty, and anxiety, and may use this additional information in their decision to refer them to radiation oncology.

While no tumor characteristics were significantly associated with surgeon referral, patients with high grade tumors were more likely to receive radiation once seen by radiation oncology. The PRIME II trial did prohibit patients from enrolling if they had *both* LVI and high grade tumors [4], and evidence supports grade (an important factor differentiating luminal A and luminal B subtypes) as a predictor of recurrence [29]. Although trends existed, neither LVI nor HER2 expression (which was not collected on prospective trials) were significant in this cohort. Future studies are being considered to evaluate recurrence in HER2+ patients. In general, variation by radiation oncologist in which at least 10 patients were treated (and therefore a reliable fraction could be estimated) was fairly small (IQR 54-73%), and patient volume was not significantly associated with a radiation oncologist's likelihood to recommend RT [30,31].

Several studies have documented variability in RT receipt based on socioeconomic status [32-34] and race/ethnicity [35,33,36,37]. In this patient population, more educated patients may be more likely to be referred for a discussion, but there was insufficient evidence that they were more likely to be treated. Longer distance from a patient's home was also not significant, in contrast to prior studies, which may be due to the urban/suburban nature of this population with a median distance from home to clinic of 13 miles.

Limitations of this study predominantly relate to its retrospective single-institution design. The ability to generalize the lack of effect of a capitated financial incentive to other clinical settings may therefore be limited. Additionally, this was conducted in a setting of relatively high omission of radiation; if radiation use is already high, it could still obstruct efforts to de-implement low value care. This study provides insights into potential mitigating factors to overtreatment, and highlights the need for additional work to assess physician- and organizational-level factors that prevent overuse in the setting of such capitated incentives. Additionally, this study lacks data on patient preference. As we move forward into an era of ultrahypofractionated radiation, we may find less avoidance of radiation, particularly in this elderly population. We did investigate use of partial breast radiation (a form of shorter-course radiation) during the study period and observed no significant increase in its use over time. Such potential changes in patient preference though are likely to compete with concomitant decreasing rates of in-breast recurrence in the setting of improved imaging, surgery, and endocrine therapy in the interim since patients enrolled on CALGB 9343 and PRIME II. Lastly, in this highly selected patient population, we may have limited ability to detect disparities in radiation receipt by socioeconomic or geographic factors. Similarly, this study may have been underpowered to detect a difference based on HER2 status and LVI, which were present in relatively low frequencies among the cohort (3% and 12%, respectively).

In conclusion, referral and treatment patterns for older women with early-stage breast cancer at a single academic institution were largely consistent with CALGB 9343 and national guidelines, with the proportion of patients receiving radiation noted to be lower than population level estimates. The lack of effect of productivity-based financial incentives is reassuring, and possibly related to a centralized system for quality assurance. Additionally, the limited number of significantly associated patient or physician variables suggests that other unmeasured ‘factors’ such as patient preference plays an important role. Larger-scale studies with more diverse patient populations are warranted to further explore and better generalize these results.

Declarations

- i. **Funding:** This work is support by a P30 MSKCC Core Grant (CA008748), and a National Cancer Institute K08 (CA252640) (E.F.G.).
- ii. **Conflicts of interest/competing interests:** The authors declare that they have no conflict of interest.
- iii. **Availability of data and material:** The authors declare that the data supporting the findings of this study are available within the article.
- iv. **Code availability:** Not applicable.
- v. **Authors’ contributions:** Mira Patel - conceptualization, data curation, writing. Elaine Cha - data curation, writing. Stephanie Lobaugh - formal analysis, writing. Zhigang Zhang - formal analysis, writing. Beryl McCormick - conceptualization, revision. Lior Braunstein - conceptualization, revision. Oren Cahlon - conceptualization, revision. Simon Powell - conceptualization, revision. Monica Morrow - conceptualization, revision. Atif Khan - conceptualization, revision. Erin Gillespie - conceptualization, data curation, funding acquisition, writing, revision.
- vi. **Ethics approval:** This retrospective chart review study involving human participants was in accordance with the ethical standards of the institutional and national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. The Human Investigation Committee (IRB) of Memorial Sloan Kettering Cancer Center approved this study.
- vii. **Consent to participate:** Not applicable.
- viii. **Consent for publication:** Not applicable.
- ix. **Acknowledgements and Funding Information:** This work is supported by a P30 MSKCC Core Grant (CA008748) from Memorial Sloan Kettering Cancer Center. We acknowledge the support of all MSKCC faculty involved in treating patients with breast cancer.

References

1. Fisher B, Anderson S, Bryant J, Margolese RG, Deutsch M, Fisher ER, Jeong JH, Wolmark N (2002) Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. *N Engl J Med* 347 (16):1233-1241. doi:10.1056/NEJMoa022152
2. Hughes KS, Schnaper LA, Bellon JR, Cirincione CT, Berry DA, McCormick B, Muss HB, Smith BL, Hudis CA, Winer EP, Wood WC (2013) Lumpectomy plus tamoxifen with or without irradiation in women age 70 years or older with early breast cancer: long-term follow-up of CALGB 9343. *J Clin Oncol* 31 (19):2382-2387. doi:10.1200/JCO.2012.45.2615

3. Hughes KS, Schnaper LA, Berry D, Cirrincione C, McCormick B, Shank B, Wheeler J, Champion LA, Smith TJ, Smith BL, Shapiro C, Muss HB, Winer E, Hudis C, Wood W, Sugarbaker D, Henderson IC, Norton L, Cancer, Leukemia Group B, Radiation Therapy Oncology G, Eastern Cooperative Oncology G (2004) Lumpectomy plus tamoxifen with or without irradiation in women 70 years of age or older with early breast cancer. *N Engl J Med* 351 (10):971-977. doi:10.1056/NEJMoa040587
4. Kunkler IH, Williams LJ, Jack WJ, Cameron DA, Dixon JM, investigators PI (2015) Breast-conserving surgery with or without irradiation in women aged 65 years or older with early breast cancer (PRIME II): a randomised controlled trial. *Lancet Oncol* 16 (3):266-273. doi:10.1016/S1470-2045(14)71221-5
5. Breast Cancer Version 3.2020. (2020) National Comprehensive Cancer Network. http://www.nccn.org/professionals/physician_gls/pdf/breast.pdf. Accessed March 10 2020
6. Soulos PR, Yu JB, Roberts KB, Raldow AC, Herrin J, Long JB, Gross CP (2012) Assessing the impact of a cooperative group trial on breast cancer care in the medicare population. *J Clin Oncol* 30 (14):1601-1607. doi:10.1200/JCO.2011.39.4890
7. Palta M, Palta P, Bhavsar NA, Horton JK, Blitzblau RC (2015) The use of adjuvant radiotherapy in elderly patients with early-stage breast cancer: changes in practice patterns after publication of Cancer and Leukemia Group B 9343. *Cancer* 121 (2):188-193. doi:10.1002/cncr.28937
8. McCormick B, Ottesen RA, Hughes ME, Javid SH, Khan SA, Mortimer J, Niland JC, Weeks JC, Edge SB (2014) Impact of guideline changes on use or omission of radiation in the elderly with early breast cancer: practice patterns at National Comprehensive Cancer Network institutions. *J Am Coll Surg* 219 (4):796-802. doi:10.1016/j.jamcollsurg.2014.05.013
9. Shumway DA, Griffith KA, Sabel MS, Jones RD, Forstner JM, Bott-Kothari TL, Hawley ST, Jeruss J, Jagsi R (2017) Surgeon and Radiation Oncologist Views on Omission of Adjuvant Radiotherapy for Older Women with Early-Stage Breast Cancer. *Ann Surg Oncol* 24 (12):3518-3526. doi:10.1245/s10434-017-6013-1
10. Wang T, Baskin A, Miller J, Metz A, Matusko N, Hughes T, Sabel M, Jeruss JS, Dossett LA (2020) Trends in Breast Cancer Treatment De-Implementation in Older Patients with Hormone Receptor-Positive Breast Cancer: A Mixed Methods Study. *Ann Surg Oncol*. doi:10.1245/s10434-020-08823-w
11. Bekelman JE, Epstein AJ, Emanuel EJ (2014) Getting the next version of payment policy "right" on the road toward accountable cancer care. *Int J Radiat Oncol Biol Phys* 89 (5):954-957. doi:10.1016/j.ijrobp.2014.04.022
12. Mitchell AP, Rotter JS, Patel E, Richardson D, Wheeler SB, Basch E, Goldstein DA (2019) Association Between Reimbursement Incentives and Physician Practice in Oncology: A Systematic Review. *JAMA Oncol* 5 (6):893-899. doi:10.1001/jamaoncol.2018.6196
13. O'Neil B, Graves AJ, Barocas DA, Chang SS, Penson DF, Resnick MJ (2016) Doing More for More: Unintended Consequences of Financial Incentives for Oncology Specialty Care. *J Natl Cancer Inst* 108 (2). doi:10.1093/jnci/djv331
14. Fung CY, Chen E, Vapiwala N, Pohar S, Trifiletti D, Truong MT, Uschold G, Schuster J, Patel A, Jani A, Mohindra P, Sanders T, Gardner L, Arnone A, Royce T (2019) The American Society for Radiation Oncology 2017 Radiation Oncologist Workforce Study. *Int J Radiat Oncol Biol Phys* 103 (3):547-556. doi:10.1016/j.ijrobp.2018.10.020
15. Downs-Canner S, Zabor EC, Wind T, Cobovic A, McCormick B, Morrow M, Heerdt A (2019) Radiation Therapy After Breast-Conserving Surgery in Women 70 Years of Age and Older: How Wisely Do We Choose? *Ann Surg*

Oncol 26 (4):969-975. doi:10.1245/s10434-018-07151-4

16. Vassar M, Holzmann M (2013) The retrospective chart review: important methodological considerations. *J Educ Eval Health Prof* 10:12. doi:10.3352/jeehp.2013.10.12
17. 2015 Area Deprivation Index v2.0 (2019) University of Wisconsin School of Medicine and Public Health. <https://www.neighborhoodatlas.medicine.wisc.edu/> Accessed November 21, 2019
18. Hunt JFV, Buckingham W, Kim AJ, Oh J, Vogt NM, Jonaitis EM, Hunt TK, Zuelsdorff M, Powell R, Norton D, Rissman RA, Asthana S, Okonkwo OC, Johnson SC, Kind AJH, Bendlin BB (2020) Association of Neighborhood-Level Disadvantage With Cerebral and Hippocampal Volume. *JAMA Neurol* 77 (4):451-460. doi:10.1001/jamaneurol.2019.4501
19. Google Maps. Google. <https://maps.google.com/>. Accessed November 2019
20. Longacre CF, Neprash HT, Shippee ND, Tuttle TM, Virnig BA (2019) Evaluating Travel Distance to Radiation Facilities Among Rural and Urban Breast Cancer Patients in the Medicare Population. *J Rural Health*. doi:10.1111/jrh.12413
21. Voti L, Richardson LC, Reis IM, Fleming LE, Mackinnon J, Coebergh JW (2006) Treatment of local breast carcinoma in Florida: the role of the distance to radiation therapy facilities. *Cancer* 106 (1):201-207. doi:10.1002/cncr.21557
22. Braunstein LZ, Thor M, Flynn J, Cost Z, Wilgucki M, Rosenbaum S, Zhang Z, Gillespie E, McCormick B, Khan A, Ho A, Cahlon O, Deasy JO, Powell SN (2019) Daily Fractionation of External Beam Accelerated Partial Breast Irradiation to 40 Gy Is Well Tolerated and Locally Effective. *Int J Radiat Oncol Biol Phys* 104 (4):859-866. doi:10.1016/j.ijrobp.2019.02.050
23. Feinberg B, Milligan S, Olson T, Wong W, Winn D, Trehan R, Scott J (2014) Physician behavior impact when revenue shifted from drugs to services. *Am J Manag Care* 20 (4):303-310
24. Loy BA, Shkedy CI, Powell AC, Happe LE, Royalty JA, Miao MT, Smith GL, Long JW, Gupta AK (2016) Do Case Rates Affect Physicians' Clinical Practice in Radiation Oncology?: An Observational Study. *PLoS One* 11 (2):e0149449. doi:10.1371/journal.pone.0149449
25. Yu JB, Pollack CE, Herrin J, Zhu W, Soulos PR, Xu X, Gross CP (2019) Persistent Use of Extended Fractionation Palliative Radiotherapy for Medicare Beneficiaries With Metastatic Breast Cancer, 2011 to 2014. *Am J Clin Oncol* 42 (6):493-499. doi:10.1097/COC.0000000000000548
26. Marks LB, Adams RD, Pawlicki T, Blumberg AL, Hoopes D, Brundage MD, Fraass BA (2013) Enhancing the role of case-oriented peer review to improve quality and safety in radiation oncology: Executive summary. *Pract Radiat Oncol* 3 (3):149-156. doi:10.1016/j.prro.2012.11.010
27. Ludmir EB, Hoffman KE, Jhingran A, Ip M-CP, Frey SD, Ning MS, Minsky BD, McAleer MF, Chronowski G, Arzu I, Reed VK, Garg AK, Roberts T, Ashish P, Olson MR, Seleuk U, Gabel M, Koong A, Herman JM, Kuban DA (2019) Implementation and efficacy of a large-scale radiation oncology case-based peer-review quality program across a multinational cancer network. *Journal of Clinical Oncology* 37 (27_suppl):1-1. doi:10.1200/JCO.2019.37.27_suppl.1
28. Radiation Oncology Model. Centers for Medicare & Medicaid Services. <https://innovation.cms.gov/innovation-models/radiation-oncology-model>. Accessed October 15 2020
29. Voduc KD, Cheang MC, Tyldesley S, Gelmon K, Nielsen TO, Kennecke H (2010) Breast cancer subtypes and the risk of local and regional relapse. *J Clin Oncol* 28 (10):1684-1691. doi:10.1200/JCO.2009.24.9284

30. Cohen GR, Friedman CP, Ryan AM, Richardson CR, Adler-Milstein J (2019) Variation in Physicians' Electronic Health Record Documentation and Potential Patient Harm from That Variation. *J Gen Intern Med* 34 (11):2355-2367. doi:10.1007/s11606-019-05025-3
31. O'Sullivan JW, Stevens S, Oke J, Hobbs FDR, Salisbury C, Little P, Goldacre B, Bankhead C, Aronson JK, Heneghan C, Perera R (2018) Practice variation in the use of tests in UK primary care: a retrospective analysis of 16 million tests performed over 3.3 million patient years in 2015/16. *BMC Med* 16 (1):229. doi:10.1186/s12916-018-1217-1
32. Deb S, Pendharkar AV, Schoen MK, Altekruze S, Ratliff J, Desai A (2017) The effect of socioeconomic status on gross total resection, radiation therapy and overall survival in patients with gliomas. *J Neurooncol* 132 (3):447-453. doi:10.1007/s11060-017-2391-2
33. Hess C, Lee A, Fish K, Daly M, Cress RD, Mayadev J (2015) Socioeconomic and racial disparities in the selection of chest wall boost radiation therapy in californian women after mastectomy. *Clin Breast Cancer* 15 (3):212-218. doi:10.1016/j.clbc.2014.11.007
34. Shen CJ, Hu C, Ladra MM, Narang AK, Pollack CE, Terezakis SA (2017) Socioeconomic factors affect the selection of proton radiation therapy for children. *Cancer* 123 (20):4048-4056. doi:10.1002/cncr.30849
35. Cobran EK, Chen RC, Overman R, Meyer AM, Kuo TM, O'Brien J, Sturmer T, Sheets NC, Goldin GH, Penn DC, Godley PA, Carpenter WR (2016) Racial Differences in Diffusion of Intensity-Modulated Radiation Therapy for Localized Prostate Cancer. *Am J Mens Health* 10 (5):399-407. doi:10.1177/1557988314568184
36. LeMasters TJ, Madhavan SS, Sambamoorthi U, Vyas AM (2017) Disparities in the Initial Local Treatment of Older Women with Early-Stage Breast Cancer: A Population-Based Study. *J Womens Health (Larchmt)* 26 (7):735-744. doi:10.1089/jwh.2015.5639
37. Schootman M, Jeffe DB, Lian M, Gillanders WE, Aft R (2009) The role of poverty rate and racial distribution in the geographic clustering of breast cancer survival among older women: a geographic and multilevel analysis. *Am J Epidemiol* 169 (5):554-561. doi:10.1093/aje/kwn369

Tables

Table 1. Patient characteristics, grouped by referral status and pre- vs. post-metric status						
		All patients	Referral status among all patients (n=703)		Pre- vs. post-metric status among referred patients (n=483)	
		n=703 <i>n (%)</i>	Not referred to RO, n=220 (31.3%) <i>n (%)</i>	Referred to RO, n = 483 (68.7%) <i>n (%)</i>	Pre-metric, n = 182 (37.7%) <i>n (%)</i>	Post-metric, n = 301 (62.3%) <i>n (%)</i>
Age	Median (Range)	74 (70-92)	77 (70-92)	73 (70-90)	73 (70-90)	73 (70-88)
	< 75	362 (51.5)	59 (26.8)	303 (62.7)	110 (60.4)	193 (64.1)
	≥ 75	341 (48.5)	161 (73.2)	180 (37.3)	72 (39.6)	108 (35.9)
Education	College or higher	232 (33)	45 (20.5)	187 (38.7)	78 (42.9)	109 (36.2)
	Below college	177 (25.2)	46 (20.9)	131 (27.1)	54 (29.7)	77 (25.6)
	Missing	294 (41.8)	129 (58.6)	165 (34.2)	50 (27.5)	115 (38.2)
Race	White	609 (86.6)	202 (91.8)	407 (84.3)	160 (87.9)	247 (82.1)
	Non-white	82 (11.7)	18 (8.2)	64 (13.3)	21 (11.5)	43 (14.3)
	Missing	12 (1.7)	0 (0)	12 (2.5)	1 (0.5)	11 (3.7)
Ethnicity	Non-hispanic	618 (87.9)	198 (90)	420 (87)	160 (87.9)	260 (86.4)
	Hispanic	32 (4.6)	2 (0.9)	30 (6.2)	10 (5.5)	20 (6.6)
	Missing	53 (7.5)	20 (9.1)	33 (6.8)	12 (6.6)	21 (7)
Preferred language	English	580 (82.5)	180 (81.8)	400 (82.8)	151 (83)	249 (82.7)
	Not English	69 (9.8)	19 (8.6)	50 (10.4)	18 (9.9)	32 (10.6)
	Missing	54 (7.7)	21 (9.5)	33 (6.8)	13 (7.1)	20 (6.6)
Marital status	Married	557 (79.2)	177 (80.5)	380 (78.7)	152 (83.5)	228 (75.7)
	Single/widowed	110 (15.6)	39 (17.7)	71 (14.7)	22 (12.1)	49 (16.3)
	Divorced	24 (3.4)	3 (1.4)	21 (4.3)	0 (0)	21 (7)
	Missing	12 (1.7)	1 (0.5)	11 (2.3)	8 (4.4)	3 (1)

Table 1. Patient characteristics, grouped by referral status and pre- vs. post-metric status						
		All patients	Referral status among all patients (n=703)		Pre- vs. post-metric status among referred patients (n=483)	
		n=703 n (%)	Not referred to RO, n=220 (31.3%) n (%)	Referred to RO, n = 483 (68.7%) n (%)	Pre-metric, n = 182 (37.7%) n (%)	Post-metric, n = 301 (62.3%) n (%)
Smoking status	Yes/prior	319 (45.4)	105 (47.7)	214 (44.3)	79 (43.4)	135 (44.9)
	No	369 (52.5)	108 (49.1)	261 (54)	95 (52.2)	166 (55.1)
	Missing	15 (2.1)	7 (3.2)	8 (1.7)	8 (4.4)	0 (0)
Practice setting	Main campus	—	—	262 (54.2)	104 (57.1)	158 (52.5)
	Regional site	—	—	201 (41.6)	65 (35.7)	136 (45.2)
	Missing	—	—	20 (4.1)	13 (7.1)	7 (2.3)
Tumor grade	3	77 (11)	16 (7.3)	61 (12.6)	19 (10.4)	42 (14)
	2	392 (55.8)	112 (50.9)	280 (58)	100 (54.9)	180 (59.8)
	1	173 (24.6)	71 (32.3)	102 (21.1)	43 (23.6)	59 (19.6)
	Missing	61 (8.7)	21 (9.5)	40 (8.3)	20 (11)	20 (6.6)
KPS score	≥ 90	427 (60.7)	52 (23.6)	375 (77.6)	141 (77.5)	234 (77.7)
	< 90	80 (11.4)	24 (10.9)	56 (11.6)	20 (11)	36 (12)
	Missing	196 (27.9)	144 (65.5)	52 (10.8)	21 (11.5)	31 (10.3)
LVI	Positive/suspicious	86 (12.2)	22 (10)	64 (13.3)	28 (15.4)	36 (12)
	Negative	590 (83.9)	187 (85)	403 (83.4)	147 (80.8)	256 (85)
	Missing	27 (3.8)	11 (5)	16 (3.3)	7 (3.8)	9 (3)
HER2 status	Positive	24 (3.4)	3 (1.4)	21 (4.3)	8 (4.4)	13 (4.3)
	Negative	677 (96.3)	216 (98.2)	461 (95.4)	174 (95.6)	287 (95.3)
	Missing	2 (0.3)	1 (0.5)	1 (0.2)	0 (0)	1 (0.3)

Table 1. Patient characteristics, grouped by referral status and pre- vs. post-metric status						
		All patients	Referral status among all patients (n=703)		Pre- vs. post-metric status among referred patients (n=483)	
		n=703 n (%)	Not referred to RO, n=220 (31.3%) n (%)	Referred to RO, n = 483 (68.7%) n (%)	Pre-metric, n = 182 (37.7%) n (%)	Post-metric, n = 301 (62.3%) n (%)
Multifocal	Yes	81 (11.5)	18 (8.2)	63 (13)	22 (12.1)	41 (13.6)
	No	622 (88.5)	202 (91.8)	420 (87)	160 (87.9)	260 (86.4)
Tumor laterality	Left	362 (51.5)	112 (50.9)	250 (51.8)	100 (54.9)	150 (49.8)
	Right	341 (48.5)	108 (49.1)	233 (48.2)	82 (45.1)	151 (50.2)
Tumor size, cm	Median (Range)	1.0 (0.1-2.0)	0.9 (0.1-1.9)	1.0 (0.1-2.0)	1.0 (0.1-2.0)	1.1 (0.1-2.0)
Oncotype DX Score	Median (Range)	15 (0-53)	11 (0-46)	15.5 (0-53)	15 (1-53)	16 (0-46)
	Ordered	301 (42.8)	43 (19.5)	258 (53.4)	104 (57.1)	154 (51.2)
	Not ordered	388 (55.2)	171 (77.7)	217 (44.9)	74 (40.7)	143 (47.5)
	Missing	14 (2.0)	6 (2.8)	8 (1.7)	4 (2.2)	4 (1.3)
Chemotherapy	Received	60 (8.5)	6 (2.7)	54 (11.2)	15 (8.2)	39 (13.0)
	Did not receive	629 (89.5)	208 (94.5)	421 (87.2)	163 (89.6)	258 (85.7)
	Missing	14 (2.0)	6 (2.7)	8 (1.7)	4 (2.2)	4 (1.3)
Endocrine therapy	Recommended	666 (94.7)	206 (93.6)	460 (95.2)	175 (96.2)	285 (94.7)
	Not recommended	37 (5.3)	14 (6.4)	23 (4.8)	7 (3.8)	16 (5.3)

Table 1. Patient characteristics, grouped by referral status and pre- vs. post-metric status						
		All patients	Referral status among all patients (n=703)		Pre- vs. post-metric status among referred patients (n=483)	
		n=703 n (%)	Not referred to RO, n=220 (31.3%) n (%)	Referred to RO, n = 483 (68.7%) n (%)	Pre-metric, n = 182 (37.7%) n (%)	Post-metric, n = 301 (62.3%) n (%)
Radiation receipt	Received	—	—	273 (56.5)	101 (55.5)	172 (57.1)
	Did not receive	—	—	210 (43.5)	81 (44.5)	129 (42.9)
Radiation dose, cGy	Median (Range)	—	—	4000 (0-6000)	4000 (0-6000)	4000 (0-5740)
	Missing	—	—	18 (3.7)	11 (6.0)	7 (2.3)
Distance to nearest clinic, mi	Median (Range)	13 (1-1993)	13 (1-1993)	12 (1-1594)	13 (1-1165)	12 (1-1594)
	1-5 mi	146 (20.8)	36 (16.4)	110 (22.8)	38 (20.9)	72 (23.9)
	6-10 mi	128 (18.2)	43 (19.5)	85 (17.6)	30 (16.5)	55 (18.3)
	11-15 mi	128 (18.2)	58 (26.4)	104 (21.5)	41 (22.5)	63 (20.9)
	16-20 mi	162 (23)	17 (7.7)	56 (11.6)	21 (11.5)	35 (11.6)
	>20 mi	73 (10.4)	63 (28.6)	117 (24.2)	46 (25.3)	71 (23.6)
	Missing	73 (10.4)	3 (1.4)	11 (2.3)	6 (3.3)	5 (1.7)
		180 (25.6)				
National percentile	Median (Range)	10 (1-100)	9 (1-100)	10 (1-100)	8 (1-100)	11 (1-100)
	Missing	18 (2.6)	1 (0.5)	17 (3.5)	9 (4.9)	8 (2.7)
Abbreviations: RO, radiation oncology; KPS, Karnofsky performance status; LVI, lymphovascular invasion						

Figures

Table 2. Univariable generalized linear mixed effects regression results for predictors of referral and radiation receipt

Variable		Referral to radiation oncology among all patients			Radiation receipt among referred patients		
		n (no. of events)	OR (95% CI)	p-value	n (no. of events)	OR (95% CI)	p-value
Tumor characteristics							
Size, cm		703 (483)	1.43 (0.93-2.20)	0.09	483 (273)	1.56 (0.99-2.44)	0.05
Grade	1	642 (443)	<i>ref</i>	0.04	443 (251)	<i>ref</i>	<0.001*
	2	173 (102)	1.86 (0.98-3.52)		102 (43)	1.83 (1.11-3.02)	
	3	392 (280)	2.95 (1.22-7.11)		280 (157)	7.75 (3.33-18.07)	
		77 (61)			61 (51)		
LVI	Negative	676 (467)	<i>ref</i>	0.32	467 (263)	<i>ref</i>	0.30
	Positive/suspicious	590 (403)	1.33 (0.73-2.45)		403 (222)	1.37 (0.74-2.52)	
		86 (64)			64 (41)		
HER2 status	Negative	701 (482)	<i>ref</i>	0.10	482 (272)	<i>ref</i>	0.09
	Positive/suspicious	677 (461)	3.32 (0.76-14.47)		461 (254)	3.55 (0.82-15.45)	
		24 (21)			21 (18)		
Multifocal	No	703 (483)	<i>ref</i>	0.15	483 (273)	<i>ref</i>	0.03
	Yes	622 (420)	1.67 (0.80-3.47)		420 (227)	2.16 (1.06-4.40)	
		81 (63)			63 (46)		
Laterality	Left	703 (483)	Did not converge	—	483 (273)	<i>ref</i>	0.14
	Right	362 (250)	Did not converge		250 (130)	1.35 (0.90-2.03)	
		341 (233)			233 (143)		
Laterality^a	Left	703 (483)	<i>ref</i>	0.55	—	—	—
	Right						

362
(250)

0.88
(0.57-
1.37)

341
(233)

Patient characteristics							
Age	< 75	703 (483)	5.64 (3.37- 9.45)	<0.001*	483 (273)	2.66 (1.54- 4.57)	0.001*
	≥ 75	362 (303)	ref		303 (200)	ref	
		341 (180)			180 (73)		
KPS score	≥ 90	507 (431)	5.34 (2.63- 10.83)	<0.001*	431 (234)	ref	0.04
	< 90	427 (375)	ref		375 (211)	0.46 (0.23- 0.95)	
		80 (56)			56 (23)		
Race	White	691 (471)	ref	0.25	471 (266)	ref	0.58
	Non-white	609 (407)	1.43 (0.75- 2.71)		407 (233)	0.85 (0.46- 1.56)	
		82 (64)			64 (33)		
Ethnicity	Non-hispanic	650 (450)	ref	0.08	450 (257)	Did not converge	—
	Hispanic	618 (420)	4.35 (0.82- 23.13)		420 (241)	Did not converge	
		32 (30)			30 (16)		
Ethnicity ^a	Non-hispanic	—	—	—	450 (257)	ref	0.89
	Hispanic				420 (241)	0.93 (0.26- 3.31)	
					30 (16)		
Preferred language	English	649 (450)	ref	0.57	450 (260)	ref	0.03
	Not English	580 (400)	0.79 (0.33- 1.89)		400 (241)	0.42 (0.20- 0.90)	
		69 (50)			50 (19)		
Education	College or higher	703 (483)	ref	0.04	483 (273)	ref	0.60
	Missing	232 (187)	0.52 (0.31- 0.86)		187 (106)	0.98 (0.61- 1.57)	
	Below college						

		294 (165)	0.62 (0.37- 1.06)		165 (99)	0.79 (0.48- 1.30)	
		177 (131)			131 (68)		
National percentile^a		685 (466)	1.00 (0.98- 1.01)	0.75	466 (262)	0.99 (0.98- 1.00)	0.07
Distance to nearest clinic	> 20 mi	689 (472)	<i>ref</i>	0.06	472 (267)	<i>ref</i>	0.19
	1-5 mi	180 (117)	2.16 (1.25- 3.73)		117 (74)	0.86 (0.47- 1.58)	
	6-10 mi	146 (110)	1.41 (0.82- 2.43)		110 (59)	0.77 (0.41- 1.43)	
	11-15 mi	128 (85)	1.37 (0.83- 2.26)		85 (47)	0.95 (0.52- 1.72)	
	16-20 mi	162 (104)	2.07 (1.03- 4.14)		104 (63)	0.44 (0.21- 0.89)	
		73 (56)			56 (24)		
Treated pre- or post-metric implementation	Pre-metric	—	—	—	483 (273)	<i>ref</i>	0.57
	Post-metric				182 (101)	1.16 (0.68- 1.98)	
					301 (172)		

Table 2 Continued. Univariable generalized linear mixed effects regression results for predictors of referral and radiation receipt

Physician characteristics

Practice setting	Main campus	—	—	—	463 (255)	<i>ref</i>	0.15
	Regional site				262 (120)	1.75 (0.75- 4.05)	
					201 (135)		
Years of experience^b	≤ 15 years	703 (483)	<i>ref</i>	0.45	468 (258)	<i>ref</i>	0.79
	> 15 years	114 (74)	1.56 (0.46- 5.23)		223 (131)	0.92 (0.47- 1.80)	
		589 (409)			245 (127)		
10+ consults/patients	Yes	703 (483)	Did not converge	—	468 (258)	<i>ref</i>	0.65

in entire study period	No	700 (480)	Did not converge	403 (220)	0.85 (0.41- 1.75)
		3 (3)		65 (38)	

Abbreviations: *OR*, odds ratio; *CI*, confidence interval; *LVI*, lymphovascular invasion; *KPS*, Karnofsky performance status

* Indicates significant p-value following false discovery rate adjustments

Estimates were obtained using a Residual Pseudo-Likelihood estimation technique with a random effects solutions expansion locus, and denominator degrees of freedom were computed using the containment method. Exceptions are denoted with superscripts as follows:

^a Estimation technique: Maximum Likelihood (LAPLACE)

^b Denominator degrees of freedom computation method: Kenward and Roger (1997)

Figure 1

a. Unadjusted proportions of patients referred to radiation oncology by high volume surgeons* b. Unadjusted proportions of patients treated with radiation therapy by high volume radiation oncologists* (*Defined as having seen >10 consultations during the study period)

Figure 2

a. Proportion of patients referred to radiation oncology and receiving radiation therapy over time b. Proportion of referred patients receiving radiation therapy over time